--- schema_version: "secwatch.filing_event.v1" accession: "0001558370-23-012631" form_type: "8-K" ticker: "TGTX" cik: "0001001316" company_name: "TG THERAPEUTICS, INC." filed_at: "2023-08-01T23:59:59+00:00" generated_at: "2026-06-12T16:25:33.650267+00:00" event_type: "m_and_a" sentiment: "positive" materiality_score: 0.85 calibrated_materiality_score: 0.85 confidence: "high" source: SEC EDGAR --- # TG Therapeutics announces $645M ex-US BRIUMVI deal with Neuraxpharm; Q2 net sales $16M ## Summary - Upfront cash payment $140M plus $12.5M at first European launch; total deal up to $645M with milestones and double-digit royalties up to 30%. - Q2 2023 BRIUMVI net sales $16M (100% QoQ growth); cumulative net product revenue $23.8M since U.S. launch in January 2023. - Over 1,200 prescriptions from 340+ providers at 225+ centers; payor coverage for ~80% of covered lives. - Pro-forma cash including upfront ~$285M; Q2 net loss $47.6M vs $40.5M in prior-year quarter. - TG retains option to buy back ex-U.S. rights for ~2 years in event of a change of control. ## SEC filing metadata - accession: 0001558370-23-012631 - form_type: 8-K - ticker: TGTX - cik: 0001001316 - company_name: TG THERAPEUTICS, INC. - filed_at: 2023-08-01T23:59:59+00:00 - event_type: m_and_a - sentiment: positive - materiality_score: 0.85 - calibrated_materiality_score: 0.85 - confidence: high - sec_items: 1.01, 2.02, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1001316/000155837023012631/0001558370-23-012631-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001316/000155837023012631/tgtx-20230728x8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001558370-23-012631 - JSON: https://secwatch.observer/filing/0001558370-23-012631.json - Plain text: https://secwatch.observer/filing/0001558370-23-012631.txt ## Key facts - Earnings Releases TG THERAPEUTICS, INC. reported six months ended June 30, 2023 results: revenue $23.8 million, net income $86.8 million. - Period: six months ended June 30, 2023 - Revenue: $23.8 million - Net income: $86.8 million - Result: reported results source text: Product Revenue, Net: Product revenue, net was approximately $16.0 million and $23.8 million for the three and six months ended June 30, 2023, compared to $0.6 million and $2.5 million for the three and six months ended June 30, 2022. Product revenue, net for the three and six months ended June 30, 2023, consisted of net product sales of BRIUMVI in the U.S., which was commercially launched in late January 2023. Product revenue, net for the three and six months ended June 30, 2022, consisted of net product sales of UKONIQTM (umbralisib), which was withdrawn from the U.S. market in May of 2022. ​ ● R&D Expenses: Total research and development (R&D) expense was $28.1 million and $44.0 million for the three and six months ended June 30, 2023, compared to $26.9 million and $74.9 million for the three and six months ended June 30, 2022. The decrease in R&D expense during the six months ended June 30, 2023 was primarily attributable to reduced manufacturing expense and clinical trial related evidence_url: https://www.sec.gov/Archives/edgar/data/1001316/000155837023012631/0001558370-23-012631-index.htm - Earnings Releases TG THERAPEUTICS, INC. reported second quarter ended June 30, 2023 results: revenue $16.0 million, net income $47.6 million. - Period: second quarter ended June 30, 2023 - Revenue: $16.0 million - Net income: $47.6 million - Result: reported results source text: Product Revenue, Net: Product revenue, net was approximately $16.0 million and $23.8 million for the three and six months ended June 30, 2023, compared to $0.6 million and $2.5 million for the three and six months ended June 30, 2022. Product revenue, net for the three and six months ended June 30, 2023, consisted of net product sales of BRIUMVI in the U.S., which was commercially launched in late January 2023. Product revenue, net for the three and six months ended June 30, 2022, consisted of net product sales of UKONIQTM (umbralisib), which was withdrawn from the U.S. market in May of 2022. ​ ● R&D Expenses: Total research and development (R&D) expense was $28.1 million and $44.0 million for the three and six months ended June 30, 2023, compared to $26.9 million and $74.9 million for the three and six months ended June 30, 2022. The decrease in R&D expense during the six months ended June 30, 2023 was primarily attributable to reduced manufacturing expense and clinical trial related evidence_url: https://www.sec.gov/Archives/edgar/data/1001316/000155837023012631/0001558370-23-012631-index.htm - Material Agreements TG THERAPEUTICS, INC. entered into Commercialization Agreement with Neuraxpharm Pharmaceuticals, S.L. valued at Total deal valued at up to $645 million in upfront and milestone payments, including $140 million up (effective 2023-07-28). - Action: entry - Agreement: license - Counterparty: Neuraxpharm Pharmaceuticals, S.L. - Value: Total deal valued at up to $645 million in upfront and milestone payments, including $140 million up - Effective: 2023-07-28 source text: On July 28, 2023, TG Therapeutics, Inc. (the “Company”) and its wholly-owned subsidiary TG Biologics, Inc. entered into a Commercialization Agreement (the “Agreement”) with Neuraxpharm Pharmaceuticals, S.L. (“Neuraxpharm”), pursuant to which the Company granted Neuraxpharm an exclusive license to commercialize BRIUMVI ® (ublituximab) for relapsing forms of multiple sclerosis (“RMS”) in Europe and certain other territories outside the United States (collectively, the “Territory”), excluding Canada and Mexico, which are retained by the Company, and certain Asian countries previously partnered. ​ Under the terms of the Agreement, Neuraxpharm is obligated to use commercially reasonable efforts to launch and commercialize BRIUMVI in the Territory, including maintaining current marketing authorizations, and obtaining additional marketing authorizations for BRIUMVI in the Territory, in accordance with a commercialization plan. The Company retains an option to buy back all rights under the Agr evidence_url: https://www.sec.gov/Archives/edgar/data/1001316/000155837023012631/0001558370-23-012631-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.